Virginia T. Ladd
,


PhRMA Statement on Proposed Rule on Medicare Advantage & Part D

Washington, D.C. (February 19, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement:

“PhRMA opposes the proposed rule on Medicare Advantage and Part D that CMS released in early January because it could disrupt care for millions of beneficiaries. The Part D program is already working well, making the proposed rule unnecessary and harmful. Quite simply, it is a solution in search of a problem.

NORD on the Need for More Collaboration to Drive Progress for Rare Disease Patients

02.17.14 | By

Many biopharmaceutical companies are actively engaged in the research and development of therapies to treat rare disease, despite challenges such as much smaller patient populations than more common diseases. Companies seek opportunities to partner with patient advocacy organizations, academia and the government in order to make even greater progress against rare disease, which collectively affect 1 in 10 Americans.

Conversations

What are our greatest challenges as we address managing chronic diseases like diabetes?

Contributors Respond

Conversations

Every 34 seconds someone has a heart attack in the United States. How can we work together to improve prevention and treatment of cardiovascular disease to save lives?

Contributors Respond

Kathleen Pasley
,


Mae Jemison
,


Paul Riley
,


Sunakshi Puri
,


Jessica Fults
,


Pages

Subscribe to PhRMA RSS